Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05865574
Other study ID # BAT-1706-004-CR
Secondary ID
Status Not yet recruiting
Phase Phase 1
First received
Last updated
Start date June 2023
Est. completion date January 2024

Study information

Verified date March 2023
Source Bio-Thera Solutions
Contact Wenting Li
Phone 15812648239
Email wtli1@bio-thera.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a randomized, double-blind, single-dose, parallel two-arm study to compare the pharmacokinetics, safety, and immunogenicity of BAT1706 Injection from different manufacturing batches (by new process and old process) in healthy male subjects.


Description:

A total of 38 subjects are planned to be enrolled and randomized in a 1: 1 ratio to receive a single intravenous drip of BAT1706 Injection (by old process) or BAT1706 Injection (by new process) at 1 mg/kg body weight. A 7-day screening period will be set up for this study. Subjects will be admitted to the hospital 1 day pre-dose (Day -1) and discharged after completing relevant observations and assessments 24 h post-dose. After discharge, subjects should return to the hospital for 12 follow-up visits according to the requirements of this study, on Days 3, 4, 5, 8, 11, 15, 22, 29, 36, 43, 57 and 71 post-dose.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 38
Est. completion date January 2024
Est. primary completion date September 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Male
Age group 18 Years to 45 Years
Eligibility Inclusion Criteria: 1. Healthy male subjects aged between 18 and 45 years with body mass index (BMI) between 18.0 and 28.0 kg/m2 and body weight between 50 and 100 kg (inclusive); 2. Subjects for whom the results of physical examination, vital signs, 12-lead ECG, and laboratory tests are normal or abnormal without clinical significance; 3. Subjects who do not smoke, or smoke no more than 5 cigarettes per day for < 10 years; 4. Subjects who agree to use effective contraception (including but not limited to: hormonal contraception, physical contraception, or abstinence) from the time of signing the informed consent form until 6 months after intravenous drip of the study drug; 5. Subjects who are willing and able to follow the visits, treatments, laboratory tests, and other relevant procedures specified in this study. Exclusion Criteria: 1. Subjects who have previous or current clinically significant gastrointestinal disorder (including diverticulitis, gastric ulcer), renal disorder, liver disorder, cardiovascular disorder, hematological disorder, lung disorder, nervous system disorder, metabolic disorder (including known diabetes mellitus), psychosis, or allergic disease (excluding mild asymptomatic seasonal allergy) at screening/enrollment, and in the opinion of the investigator, are not suitable for participation in this clinical study; 2. Subjects who have psychiatric disorders, or in the opinion of the investigator, are not suitable for participation in this clinical study (e.g., he is considered unable to understand or follow the relevant requirements of the study, or some of his existing conditions may result in additional risks associated with participation in this study); 3. Subjects who have previous or current clinically significant allergies (excluding mild asymptomatic seasonal allergy); or subjects who have known or suspected allergy or hypersensitivity to any component of the study drug; or subjects who have known or suspected hypersensitivity to Chinese hamster ovary cell products or other recombinant human or humanized antibodies; 4. Subjects who have a tendency to haemorrhage or thrombosis, or have a history of non-traumatic haemorrhage with appropriate clinical treatment, or have a history of thrombosis, or have any disease that may increase the risk of haemorrhage or thrombosis (e.g., abnormal coagulation, thrombocytopenia, or INR > 1.5); 5. Subjects who have any previous malignancy including lymphoma, leukemia, and skin cancer; 6. Subjects who have abnormal and clinically significant ECG (as judged by the investigator), or corrected QT interval according to Bazett's formula > 470 ms (Bazett's formula: Q-Tc = QT/(R-R)0.5, where R-R represents the interval between two R waves in s); 7. Subjects who have a history of hypertension, or systolic blood pressure > 145 mmHg or diastolic blood pressure > 95 mmHg at screening/enrollment; 8. Subjects who have clinically significant chronic or acute infection at screening/enrollment; or have any positive result for HBV surface antigen, HCV antibody, HIV antibody, and treponema pallidum antibody at screening; 9. Subjects who have previously used Bevacizumab or VEGF-targeting agents; 10. Subjects who have used any biological product within 3 months prior to enrollment, or have used any monoclonal antibody within 9 months prior to enrollment; 11. Subjects who have used prescription or over-the-counter drugs within 14 days prior to enrollment, or less than 5 half-lives have passed from the last dose to the dosing day of this study, whichever is longer; 12. Subjects who have used any Chinese herbal medicine within 14 days prior to enrollment; 13. Subjects who have participated in other drug clinical trials within 3 months prior to enrollment, or propose to participate in other drug clinical trials during this study; 14. Subjects who have received live virus vaccine within 12 weeks prior to screening, or plan to receive live virus vaccine during the study; 15. Subjects who have undergone major injury, surgery, or fracture within 4 weeks prior to enrollment, or propose to undergo surgery during the study; 16. Subjects who have donated blood or have blood samples > 400 mL collected as subjects within 3 months prior to screening, or plan to donate blood during the study; 17. Subjects who have a history of alcohol dependence, or have a positive alcohol test result at screening/baseline; 18. Subjects who have consumed alcoholic beverages within 48 h prior to enrollment; 19. Subjects who have a history of drug abuse, or have a positive drug abuse test result at screening/baseline; 20. Subjects who cannot follow the restrictions on smoking, alcohol consumption and concomitant medications for this study during the study; 21. Subjects who cannot stop high-intensity physical activities from the dosing day of the study drug until 30 days post-dose.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
BAT1706 Injection
1 vial/carton, 400 mg/16 mL/vial

Locations

Country Name City State
China The Second Affiliated Hospital of Anhui Medical University Hefei Anhui

Sponsors (1)

Lead Sponsor Collaborator
Bio-Thera Solutions

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary AUC0-inf Area under the plasma concentration-time curve from zero to infinity, AUC0-8 = AUC0-t + Ct/?z Day1, 2, 3, 4, 5, 8,15, 22, 29, 36, 43, 57, 71
Primary AUC0-t Area under the blood concentration-time curve from time 0 to the last time point at which the concentration can be measured Day1, 2, 3, 4, 5, 8,15, 22, 29, 36, 43, 57, 71
Primary Cmax Maximum blood concentration Day1, 2, 3, 4, 5, 8,15, 22, 29, 36, 43, 57, 71
Primary Tmax Observed time to peak concentration Day1, 2, 3, 4, 5, 8,15, 22, 29, 36, 43, 57, 71
Primary t1/2 Elimination half-life t1/2 = 0.693/?z Day1, 2, 3, 4, 5, 8,15, 22, 29, 36, 43, 57, 71
Secondary Adverse events AE and SAE Day1, 2, 3, 4, 5, 8,15, 22, 29, 36, 43, 57, 71
Secondary Immunogenicity Anti-drug antibody (ADA) positivity, ADA titer and neutralizing antibody (NAb) positivity for ADA. Day1, 2, 3, 4, 5, 8,15, 22, 29, 36, 43, 57, 71
See also
  Status Clinical Trial Phase
Completed NCT02575209 - Gender Differences in Social Cognition in Patients With Schizophrenia of Recent Diagnosis and Healthy Controls Subjects N/A
Completed NCT00900107 - Time-Dependent Mobilization of Circulating Progenitor Cells During Strenuous Exercise in Healthy Individuals N/A
Completed NCT02517775 - Effects of Cranberry Consumption in Vascular Function in Healthy Individuals N/A
Active, not recruiting NCT03298373 - 28-Day Repeat-Dose, Dose Escalation Study of 11-β Methyl Nortestosterone Dodecylcarbonate (11β-MNTDC) in Healthy Men Phase 1
Completed NCT03339167 - Metabolic Availability of Lysine From Millet in Adult Men N/A
Completed NCT01710280 - Palmitic Acid in the Sn-2 Position of Triacylglycerols and Postprandial Lipemia N/A
Completed NCT01130948 - Sleep, Breathing and Psychomotor Performance at Altitude: A Physiologic Study in Healthy Subjects N/A
Completed NCT01382069 - Phase 1 Study of Dimethandrolone Undecanoate in Healthy Men Phase 1
Recruiting NCT05523674 - Effects of Warm-up Intensity and Blood Flow Restriction N/A
Completed NCT01293591 - Garlic Intake And Biomarkers Of Cancer Risk N/A
Completed NCT01296997 - Calcium Phosphate and Incretins N/A
Completed NCT00935662 - A First Time in Man, Study to Assess the Safety of AZD8329 After Single Ascending Oral Doses Phase 1
Completed NCT01221558 - Effects of Lycopene on Oxidative Stress and Markers of Endothelial Function Healthy Men Phase 3
Active, not recruiting NCT05825781 - Study, Evaluating Pharmacokinetics, Immunogenicity and Safety Profiles of Pertuzumab Compared to Perjeta® in Healthy Man Phase 1
Completed NCT02994602 - Study of Serum Testosterone and Nestorone in Females After Secondary Exposure to Nestorone ® (NES) + Testosterone (T) Combined Gel Applied to Shoulders and Upper Arms in Males Phase 1
Completed NCT02365987 - The Acute Effects of Interesterification of Commercially Used Fats on Postprandial Lipaemia and Satiety N/A
Completed NCT02072278 - Electroencephalography Study Investigating the Effects of Vortioxetine in Healthy Male Subjects Phase 1
Completed NCT02093169 - D2 Dopamine Receptor Occupancy After Oral Dosing of Lu AF35700 in Healthy Men Using [11C]-PHNO as Tracer Compound Phase 1
Completed NCT03411005 - Metabolic Availability of Lysine From Sorghum in Adult Men N/A
Recruiting NCT02927210 - Injectable DMAU for Male Contraception in Healthy Male Volunteers (CCN015) Phase 1